574 results on '"Krämer, Alwin"'
Search Results
2. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
3. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
4. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
5. CUP-Syndrom – die neue ESMO-Leitlinie
6. Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich
7. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
8. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
9. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
10. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
11. Synthetic patches, real images: screening for centrosome aberrations in EM images of human cancer cells
12. Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie
13. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
14. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
15. Human SLFN5 and its Xenopus Laevis ortholog regulate entry into mitosis and oocyte meiotic resumption
16. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
17. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
18. Prediction of acute myeloid leukaemia risk in healthy individuals.
19. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
20. Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
21. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
22. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
23. Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
24. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
25. CUP-Syndrom – Tumorerkrankung mit unbekanntem Primärtumor
26. The clinical mutatome of core binding factor leukemia
27. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia
28. Enasidenib
29. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
30. Diagnostic Work-up of CUP: An Approach to Current Recommendations and Underlying Evidence
31. Future Directions
32. Prognostic Factors and Their Role in the Management of CUP
33. Biologic Features of CUP
34. Introduction
35. Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
36. Management of a pregnant ALK-positive lung cancer patient with alectinib-induced pneumonitis and bilateral globus pallidus necrosis postpartum
37. 2. Diagnose und WHO-Klassifikation myeloischer Neoplasien
38. SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia
39. Cancer of unknown primary—The new ESMO guidelines
40. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
41. Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
42. Supplementary Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
43. Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie
44. Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability
45. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
46. Synthetic Patches, Real Images: Screening for Centrosome Aberrations in EM Images of Human Cancer Cells
47. Supplementary data from Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
48. Supplementary movie S2 from Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
49. Supplementary Table S1 from Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
50. Supplementary Video 1 from Cep63 Recruits Cdk1 to the Centrosome: Implications for Regulation of Mitotic Entry, Centrosome Amplification, and Genome Maintenance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.